Sunday, February 15, 2009

News of Note this past week

~ Gender disparities persist in treatment of stroke. Guess which direction this one cuts.

~ TANSTAAFL: Pfizer to disclose payments to doctors, researchers starting in 2010. All right, let’s hear it!

~ Second Stryker sales rep pleads guilty to misbranding a medical device. A


~ Ovaries can be safely saved in some endometrial cancers.

~ 9 flawed genes found in risk of heart attack. Ah, the plot thickens!

~ Are you what you eat?: Mediterranean diet could cut risk of dementia. Quick! Get me some fish and olive oil.

~ Bone drugs may help fight breast cancer. Nice added benefit.

~ Damaged spinal cords in mice improved by transplants of neural stem cells produced with human induced pluripotent stem cells. We can rebuild them .

~ Are fears over bioterrorism stifling scientific research?

~ Naturally occurring brain protein may slow or stop the progress of


~ Gene therapy offers hope of cure for HIV: bone marrow transplant breakthrough.

~ GM goats raised to produce human breast milk. Just had to include this

story, in light of the one right below!

~ FDA approves drug made in milk of genetically altered goats. This is the first time such a drug has been approved. They also looked back at 7 generations of the goats to look for adverse effects on the animals.

~ Epilepsy group asking lawmakers to prohibit pharmacies from switching prescribed meds to generics amid reports of increased seizure incidence with generics over brand name epilepsy meds. Hmmm . . .thought generics were supposed to be bioequivalent. Seems that is not always the case!

~ Wacky names for newly discovered fruit fly genes. Examples? “Cheap Date,” “I’m not Dead Yet” (otherwise known as INDY). Who said scientists have no sense of humor?

[Thank you to Lisa von Biela, JD candidate, 2009, UMN, Editor of the BioBlurb, from which this content is partially taken and edited. BioBlurb is a weekly electronic publication of the American Bar Association's Committee on Biotechnology, Section of Science & Technology Law. Archived issues of the BioBlurb, as well as further information about the Committee on Biotechnology, are available here.]

No comments: